12:00 AM
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NX-1207: Phase III started

Recordati began a European Phase III trial evaluating a single intraprostatic injection of NX-1207 in patients with lower urinary tract symptoms associated with BPH...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >